8-K 1 v428748_8k.htm FORM 8-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report: January 7, 2016
(Date of earliest event reported)

CELLECTAR BIOSCIENCES, INC.
(Exact name of registrant as specified in its charter)

Delaware |  | 1-36598 |  | 04-3321804
(State or other jurisdiction of incorporation) |  | (Commission File Number) |  | (IRS Employer Identification Number)

3301 Agriculture Drive
Madison, WI 53716
(Address of principal executive offices)

(608) 441-8120
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

| ITEM 7.01 | REGULATION FD DISCLOSURE

On January 7, 2016, we issued a press release announcing that our CEO, Jim Caruso, will be presenting at the Biotech Showcase in San Francisco on January 12, 2016 at 5:00 PM PT in the Mission I room. A copy of the press release, and the Corporate Presentation to be used, are furnished as Exhibits 99.1 and 99.2, respectively, and are incorporated by reference herein.

| ITEM 9.01 | FINANCIAL STATEMENTS AND EXHIBITS

(d) Exhibits

Number |  | Title
99.1 |  | Press release dated January 7, 2016, entitled “Cellectar Biosciences to Present at the 2016 Biotech Showcase”
99.2 |  | Cellectar Biosciences, Inc. Corporate Presentation, dated January 11, 2016

| 2 |

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: January 11, 2016 | CELLECTAR BIOSCIENCES, INC.
| By: | /s/ Chad J. Kolean
|  | Name: Chad J. Kolean
|  | Title: Vice President and Chief Financial Officer

| 3 |

EXHIBIT INDEX

Number |  | Title
99.1 |  | Press release dated January 7, 2016, entitled “Cellectar Biosciences to Present at the 2016 Biotech Showcase”
99.2 |  | Cellectar Biosciences, Inc. Corporate Presentation, dated January 11, 2016

| 4 |